PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Area of Science:

• Oncology
• Immunology

Background:

• Tumor cells employ
• cancer immune escape
• mechanisms to evade host immunity.
• The programmed cell death protein 1 (PD-1) receptor and its ligand (PD-L1) mediate a key immunosuppressive pathway.
• PD-1 is expressed on T cells, while PD-L1 is found on tumor cells, contributing to immune evasion in the tumor microenvironment.

Purpose of the Study:

• To review recent clinical trials of anti-PD-1 and anti-PD-L1 antibodies in treating various malignancies.
• To discuss the clinical perspectives and challenges associated with PD-1/PD-L1 blockade therapy.

Main Methods:

• Review of preclinical studies demonstrating the efficacy of PD-1/PD-L1 blockade.
• Analysis of clinical trial data for anti-PD-1/anti-PD-L1 agents in solid and hematological cancers.
• Inclusion of data from a specific clinical trial conducted by the authors' department.

Main Results:

• Preclinical data indicate that blocking the PD-1/PD-L1 interaction enhances T-cell responses and antitumor activity.
• Clinical trials show significant antitumor efficacy of PD-1/PD-L1 signal-blockade agents in specific cancer types.
• The review highlights the therapeutic potential and observed outcomes from recent clinical investigations.

Conclusions:

• The PD-1/PD-L1 pathway is a critical target for overcoming cancer immune escape.
• PD-1/PD-L1 blockade therapies have demonstrated considerable success in clinical settings for certain malignancies.
• Further research and clinical evaluation are essential to optimize the use and address challenges of this immunotherapy approach.